Predictive Oncology (AGPU) Competitors

$5.34 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$5.40 +0.06 (+1.05%)

As of 05/22/2026 07:26 PM Eastern

AGPU vs. NYXH, INO, LAKE, VANI, and PYPD

Should you buy Predictive Oncology stock or one of its competitors? MarketBeat compares Predictive Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Predictive Oncology include Nyxoah (NYXH), Inovio Pharmaceuticals (INO), Lakeland Industries (LAKE), Vivani Medical (VANI), and PolyPid (PYPD). These companies are all part of the "medical equipment" industry.

How does Predictive Oncology compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Nyxoah presently has a consensus target price of $7.67, suggesting a potential upside of 167.13%. Given Nyxoah's stronger consensus rating and higher probable upside, equities research analysts clearly believe Nyxoah is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nyxoah has a net margin of -543.21% compared to Predictive Oncology's net margin of -470,383.31%. Nyxoah's return on equity of -163.73% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Predictive Oncology	-470,383.31%	-7,363.67%	-626.32%

Nyxoah has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.45, suggesting that its share price is 245% more volatile than the broader market.

Nyxoah has higher revenue and earnings than Predictive Oncology. Nyxoah is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	9.82	-$101.92M	-$2.48	N/A
Predictive Oncology	$120K	462.80	-$233.10M	-$8.18	N/A

In the previous week, Nyxoah had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for Nyxoah and 1 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.34 beat Nyxoah's score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.0% of Predictive Oncology shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Nyxoah beats Predictive Oncology on 11 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to Inovio Pharmaceuticals?

Predictive Oncology (NASDAQ:AGPU) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Predictive Oncology's net margin of -470,383.31%. Inovio Pharmaceuticals' return on equity of -489.79% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-470,383.31%	-7,363.67%	-626.32%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Inovio Pharmaceuticals has lower revenue, but higher earnings than Predictive Oncology. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$120K	462.80	-$233.10M	-$8.18	N/A
Inovio Pharmaceuticals	$60K	1,851.08	-$84.95M	-$1.45	N/A

Predictive Oncology has a beta of 3.45, indicating that its share price is 245% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

In the previous week, Inovio Pharmaceuticals had 4 more articles in the media than Predictive Oncology. MarketBeat recorded 5 mentions for Inovio Pharmaceuticals and 1 mentions for Predictive Oncology. Inovio Pharmaceuticals' average media sentiment score of 0.98 beat Predictive Oncology's score of 0.34 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inovio Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 233.33%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Inovio Pharmaceuticals beats Predictive Oncology on 13 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to Lakeland Industries?

Lakeland Industries (NASDAQ:LAKE) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Lakeland Industries has higher revenue and earnings than Predictive Oncology. Lakeland Industries is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakeland Industries	$192.65M	0.53	-$25.31M	-$2.58	N/A
Predictive Oncology	$120K	462.80	-$233.10M	-$8.18	N/A

Lakeland Industries has a net margin of -13.14% compared to Predictive Oncology's net margin of -470,383.31%. Lakeland Industries' return on equity of -9.57% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakeland Industries	-13.14%	-9.57%	-6.06%
Predictive Oncology	-470,383.31%	-7,363.67%	-626.32%

Lakeland Industries presently has a consensus price target of $15.20, indicating a potential upside of 45.73%. Given Lakeland Industries' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lakeland Industries is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakeland Industries	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.7% of Lakeland Industries shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 3.4% of Lakeland Industries shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lakeland Industries and Lakeland Industries both had 1 articles in the media. Predictive Oncology's average media sentiment score of 0.34 beat Lakeland Industries' score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakeland Industries	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakeland Industries has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.45, meaning that its stock price is 245% more volatile than the broader market.

Summary

Lakeland Industries beats Predictive Oncology on 11 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vivani Medical currently has a consensus price target of $3.50, indicating a potential upside of 191.67%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts plainly believe Vivani Medical is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vivani Medical has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.45, indicating that its stock price is 245% more volatile than the broader market.

Vivani Medical has higher earnings, but lower revenue than Predictive Oncology. Vivani Medical is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A
Predictive Oncology	$120K	462.80	-$233.10M	-$8.18	N/A

Vivani Medical has a net margin of 0.00% compared to Predictive Oncology's net margin of -470,383.31%. Vivani Medical's return on equity of -264.04% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-264.04%	-79.85%
Predictive Oncology	-470,383.31%	-7,363.67%	-626.32%

In the previous week, Vivani Medical had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for Vivani Medical and 1 mentions for Predictive Oncology. Vivani Medical's average media sentiment score of 1.53 beat Predictive Oncology's score of 0.34 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vivani Medical beats Predictive Oncology on 11 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

PolyPid presently has a consensus target price of $12.25, indicating a potential upside of 144.02%. Given PolyPid's stronger consensus rating and higher possible upside, equities analysts clearly believe PolyPid is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PolyPid had 8 more articles in the media than Predictive Oncology. MarketBeat recorded 9 mentions for PolyPid and 1 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.34 beat PolyPid's score of 0.03 indicating that Predictive Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PolyPid has higher earnings, but lower revenue than Predictive Oncology. PolyPid is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Predictive Oncology	$120K	462.80	-$233.10M	-$8.18	N/A

PolyPid has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.45, indicating that its share price is 245% more volatile than the broader market.

PolyPid has a net margin of 0.00% compared to Predictive Oncology's net margin of -470,383.31%. PolyPid's return on equity of -241.96% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Predictive Oncology	-470,383.31%	-7,363.67%	-626.32%

Summary

PolyPid beats Predictive Oncology on 11 of the 15 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGPU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGPU vs. The Competition

Export

Metric	Predictive Oncology	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$55.56M	$3.22B	$4.26B	$12.34B
Dividend Yield	N/A	N/A	5.93%	5.28%
P/E Ratio	-0.65	2.51	21.90	25.66
Price / Sales	462.80	455.93	180.61	86.31
Price / Cash	N/A	3.94	55.68	56.67
Price / Book	1.38	3.20	34.85	7.14
Net Income	-$233.10M	-$76.79M	$112.32M	$335.98M
7 Day Performance	12.18%	1.67%	3.55%	4.15%
1 Month Performance	-19.58%	-2.02%	3.59%	2.54%
1 Year Performance	N/A	100.00%	15.80%	35.06%

Predictive Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGPU Predictive Oncology	0.7415 of 5 stars	$5.34 flat	N/A	N/A	$55.56M	$120K	N/A	30	Analyst Upgrade Gap Down
NYXH Nyxoah	1.8891 of 5 stars	$2.90 +3.3%	$7.67 +164.0%	-62.9%	$112.56M	$11.33M	N/A	110
INO Inovio Pharmaceuticals	2.2406 of 5 stars	$1.25 +2.0%	$4.50 +261.4%	-31.5%	$102.43M	$60K	N/A	320
LAKE Lakeland Industries	2.999 of 5 stars	$10.35 -3.0%	$15.20 +46.9%	-42.8%	$102.24M	$192.65M	N/A	2,600	Gap Down
VANI Vivani Medical	3.8756 of 5 stars	$1.18 +2.2%	$3.50 +197.9%	+6.2%	$101.33M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGPU) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Predictive Oncology (AGPU) Competitors

AGPU vs. NYXH, INO, LAKE, VANI, and PYPD

How does Predictive Oncology compare to Nyxoah?

Summary

How does Predictive Oncology compare to Inovio Pharmaceuticals?

Summary

How does Predictive Oncology compare to Lakeland Industries?

Summary

How does Predictive Oncology compare to Vivani Medical?

Summary

How does Predictive Oncology compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGPU vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Predictive Oncology (AGPU) Competitors

AGPU vs. NYXH, INO, LAKE, VANI, and PYPD

How does Predictive Oncology compare to Nyxoah?

Do analysts recommend NYXH or AGPU?

Is NYXH or AGPU more profitable?

Which has more volatility & risk, NYXH or AGPU?

Which has preferable earnings and valuation, NYXH or AGPU?

Does the media favor NYXH or AGPU?

Do institutionals & insiders hold more shares of NYXH or AGPU?

Summary

How does Predictive Oncology compare to Inovio Pharmaceuticals?

Do insiders & institutionals hold more shares of AGPU or INO?

Is AGPU or INO more profitable?

Which has better valuation & earnings, AGPU or INO?

Which has more risk & volatility, AGPU or INO?

Does the media refer more to AGPU or INO?

Do analysts prefer AGPU or INO?

Summary

How does Predictive Oncology compare to Lakeland Industries?

Which has stronger valuation and earnings, LAKE or AGPU?

Is LAKE or AGPU more profitable?

Do analysts prefer LAKE or AGPU?

Do insiders and institutionals believe in LAKE or AGPU?

Does the media favor LAKE or AGPU?

Which has more volatility & risk, LAKE or AGPU?

Summary

How does Predictive Oncology compare to Vivani Medical?

Do insiders and institutionals believe in VANI or AGPU?

Do analysts recommend VANI or AGPU?

Which has more risk & volatility, VANI or AGPU?

Which has higher earnings & valuation, VANI or AGPU?

Is VANI or AGPU more profitable?

Does the media favor VANI or AGPU?

Summary

How does Predictive Oncology compare to PolyPid?

Do analysts recommend PYPD or AGPU?

Does the media favor PYPD or AGPU?

Do insiders & institutionals believe in PYPD or AGPU?

Which has preferable earnings and valuation, PYPD or AGPU?

Which has more volatility & risk, PYPD or AGPU?

Is PYPD or AGPU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGPU vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools